Abstract:Abstract Background Myasthenia gravis (MG) is the most prevalent autoimmune disorder affecting the neuromuscular junction. A rapid deterioration in respiratory muscle can lead to a myasthenic crisis (MC), which represents a life-threatening condition with high mortality in MG. Multiple CD4+ T subsets and hypercytokinemia have been identified in the peripheral pro-inflammatory milieu during the crisis. However, the pathogenesis is complicated due to the many types of cells involved, leaving the underlying mechanism largely unexplored. Methods We conducted single-cell transcriptomic and immune repertoire sequencing on 33,577 peripheral blood mononuclear cells (PBMCs) from two acetylcholine receptor antibody-positive (AChR +) MG patients during MC and again three months post-MC. We followed the Scanpy workflow for quality control, dimension reduction, and clustering of the single-cell data. Subsequently, we annotated high-resolution cell types utilizing transfer-learning models derived from publicly available single-cell immune datasets. RNA velocity calculations from unspliced and spliced mRNAs were applied to infer cellular state progression. We analyzed cell communication and MG-relevant cytokines and chemokines to identify potential inflammation initiators. Results We identified a unique subset of monocytes, termed monocytes 3 (FCGR3B+ monocytes), which exhibited significant differential expression of pro-inflammatory signaling pathways during and after the crisis. In line with the activated innate immune state indicated by MC, a high neutrophil–lymphocyte ratio (NLR) was confirmed in an additional 22 AChR + MC patients in subsequent hemogram analysis and was associated with MG-relevant clinical scores. Furthermore, oligoclonal expansions were identified in age-associated B cells exhibiting high autoimmune activity, and in CD4+ and CD8+ T cells demonstrating persistent T exhaustion. Conclusions In summary, our integrated analysis of single-cell transcriptomics and TCR/BCR sequencing has underscored the role of innate immune activation which is associated with hypercytokinemia in MC. The identification of a specific monocyte cluster that dominates the peripheral immune profile may provide some hints into the etiology and pathology of MC. However, future functional studies are required to explore causality.

B-cell immune dysregulation with low soluble CD22 levels in refractory seronegative myasthenia gravis

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Regulatory B Cells Are Decreased and Functionally Impaired in Myasthenia Gravis Patients

Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis

Circulating Regulatory T Cells and B Cell-Activating Factor Receptor on B Cells in Patients with Myasthenia Gravis

B cells in the pathophysiology of myasthenia gravis

Serum amyloid A facilitates expansion of CD4+ T cell and CD19+ B cell subsets implicated in the severity of myasthenia gravis patients

Single-cell RNA-Seq reveals transcriptional heterogeneity and immune subtypes associated with disease activity in human myasthenia gravis

Immune repertoire profiling in myasthenia gravis

Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab

Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy

Peripheral Immune Landscape for Hypercytokinemia in Myasthenic Crisis Utilizing Single-Cell Transcriptomics.

Circulating CXCR5+ natural killer cells are expanded in patients with myasthenia gravis

[Recent advance in research for myasthenia gravis, in relation to various antibodies affecting synaptic structure and function]

IL-37 Represses the Autoimmunity in Myasthenia Gravis Via Directly Targeting Follicular Th and B Cells

The role of innate immunity in myasthenia gravis

Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities

Stereotypic T cell receptor clonotypes in the thymus and peripheral blood of Myasthenia gravis patients

Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod

The Intricate Dance of Non-Coding RNAs in Myasthenia Gravis Pathogenesis and Treatment

Aberrant Dendritic Cell Subsets in Patients with Myasthenia Gravis and Related Clinical Features